A common dwelling for pain can cause dementia

A new study showed a disturbing relationship between the regular use of “Gababin”, to treat lower back pain and increase the risk of dementia and moderate cognitive weakness. The results indicate that these risks are increasing especially in the younger age groups, asking more caution when describing this common medicine. According to the results, people who received 6 or more medical prescriptions as “Gababin” were 29% more likely to diagnose dementia, and 85% to diagnose moderate cognitive weakness within ten years of the diagnosis of their initial pain. The researchers said that these risks in age groups were more than weak, which is usually very small to develop one of the two cases. There was no increased risk between the 18-34-year-old category that described the medicine, but the risk of dementia doubled more than twice, and the risk of light cognitive disability doubled more than three times between the 35-49-year-old who prescribed the medicine. A similar pattern was observed between the age group of 50-64. The risks also increased parallel to the recipes of medical prescriptions; Patients who received 12 or more prescriptions were 40% more likely to develop dementia, and 65% are more likely to develop moderate cognitive impairment compared to those who described Jababinin between 3 and 11 times. What is Gabein? Gabapentin is a drug classified as anti -synthesis or anti -epilepsy, and although its primary use was to treat partial attacks at epilepsy patients, its applications have expanded significantly to accompany the ethnic infections and diabetic neuropathy. It is believed that the Gabinin works to calm the nerves that are too active in the nervous system by affecting calcium channels and reducing the release of exciting nerve vectors, helping to relieve pain and seizures, and it is a non -aphuny alternative that is common in the treatment of chronic pain due to the relative low probability. The researchers indicate that the gabbabin has become increasingly common in the treatment of chronic pain, especially pain, especially pain, especially pain, especially pain, especially pain, especially pain, especially pain, especially pain, especially pain, especially pain nervousness, due to the potential to provide neurological protection benefits and the possibility of addiction compared to opioid substances. However, the concerns about its side effects began to appear, including the possibility of the association with nervous degeneration, although the results were mixed so far. The researchers relied on the actual time of the “Trinetx” network, a united healthy search network containing electronic health records of 68 healthcare institutions in the United States. The researchers analyzed unidentified records for adult patients described as Japabethen who did not describe – 26 thousand and 414 in each group – to treat chronic lower back pain between 2004 and 2024, taking into account the population composition, associated conditions and the use of other pain lighteners. The results indicated that there was a connection between the description of the Japabethen and the dementia or cognitive weakness within ten years. In addition, the increasing repetition of Gabenein recipes is associated with dementia. According to the researchers, the study is observation and therefore cannot be withdrawn on the cause and result. The researchers also acknowledged that their study was retrospective, and that they could not take the dose or time of the use of the Gababin. However, the researchers claim that the results support the need for accurate monitoring of adult patients described as Japabethen to judge any possible cognitive decline and the importance of balance between the benefits of gabenein in managing pain and potential risks to cognitive health, which asks more research and clinical vigilance.